Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
researchsquare; 2020.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-94972.v1

ABSTRACT

Background Peripheral hematological changes in severe COVID-19 patients may reflect the immune reaction during SARS-CoV-2 infection. Characteristics of peripheral blood cells as early signals were needed to be investigated for clarifying its associations with the fatal outcomes in COVID-19 patients. Methods A retrospective cohort study was performed and the hospitalized COVID-19 patients were recruited in wards of Tongji Hospital (Wuhan, China). Characteristics of peripheral blood cells in survivors and non-survivors were analyzed. Also the comparison among patients with different level of eosinophils was performed. Results198 patients were included in this study, of whom 185 were discharged and 13 died in hospital. Compared to the survivors, counts of lymphocytes, monocytes, eosinophils and basophils were significantly decreased in non-survivors. According to the level of eosinophils, patients were divided into low EOS group (< 0.02×109/L) and normal EOS group (≥ 0.02×109/L). Patients in the low EOS group showed a significantly higher fever compared to normal EOS group. The proportion of patients in low EOS group who used glucocorticoids increased significantly than the other group. Death rate in the low EOS group was higher and no patient death in normal EOS group. Moreover, positive correlation was found between the counts of lymphocytes and eosinophils in patients with glucocorticoids use but not in patients without the treatment. Conclusions Hematological changes differed between survivors and non-survivors with COVID-19. Lymphopenia and eosinopenia could serve to predict the poor prognosis of COVID-19 patients. Initial counts of eosinophils may guide us in usage of glucocorticoids for COVID-19 treatment. 


Subject(s)
COVID-19 , Fever , Lymphopenia
3.
researchsquare; 2020.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-50577.v2

ABSTRACT

BackgroundCoronavirus disease 2019 (COVID-19) is an emerging infectious disease that rapidly spreads worldwide and co-infection of COVID-19 and influenza may occur in some cases. We aimed to describe clinical features and outcomes of severe COVID-19 patients with co-infection of influenza virus.MethodsRetrospective cohort study was performed and a total of 140 patients with severe COVID-19 were enrolled in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan city, Hubei province, China. The demographic, clinical features, laboratory indices, treatment and outcomes of these patients were collected.ResultsOf 140 severe COVID-19 hospitalized patients, including 73 patients (52.14%) with median age 62 years were influenza virus IgM-positive and 67 patients (47.86%) with median age 66 years were influenza virus IgM-negative. 76 (54.4%) of severe COVID-19 patients were males. Chronic comorbidities consisting mainly of hypertension (45.3%), diabetes (15.8%), chronic respiratory disease (7.2%), cardiovascular disease (5.8%), malignancy (4.3%) and chronic kidney disease (2.2%). Clinical features, including fever (≥38°C), chill, cough, chest pain, dyspnea, diarrhea and fatigue or myalgia were collected. Fatigue or myalgia was less found in COVID-19 patients with IgM-positive (33.3% vs 50/7%, P = 0.0375). Higher proportion of prolonged activated partial thromboplastin time (APTT) > 42 s was observed in COVID-19 patients with influenza virus IgM-negative (43.8% vs 23.6%, P = 0.0127). Severe COVID-19 Patients with influenza virus IgM positive have a higher cumulative survivor rate than that of patients with influenza virus IgM negative (Log-rank P= 0.0308). Considering age is a potential confounding variable, difference in age was adjusted between different influenza virus IgM status groups, the HR was 0.29 (95% CI, 0.081-1.100). Similarly, difference in gender was adjusted as above, the HR was 0.262 (95% CI, 0.072-0.952) in the COX regression model.ConclusionsInfluenza virus IgM positive may be associated with decreasing in-hospital death.


Subject(s)
Coinfection , Communicable Diseases, Emerging , Cardiovascular Diseases , Renal Insufficiency, Chronic , Dyspnea , Fever , Diabetes Mellitus , Chest Pain , Neoplasms , Chronic Disease , Hypertension , Myalgia , COVID-19 , Influenza, Human , Fatigue , Diarrhea , Disease
4.
researchsquare; 2020.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-27484.v1

ABSTRACT

Background Coronavirus disease 2019 (COVID-19) is an emerging infection disease that rapidly spreads worldwide. Clinical features and outcomes of severe COVID-19 patients with influenza virus IgM positive during the influenza season need to be described.Methods Retrospective cohort study of 140 patients with severe COVID-19 hospitalized in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan, Hubei province, China. The demographic, clinical feature, laboratory, treatment and outcome were collected and analyzed.Results Of 140 severe COVID-19 hospitalized patients, 73 patients were with median age of 66 years old with identification of influenza virus IgM-positive and 67 patients were with median age of 62 years old in influenza virus IgM-negative group. Nearly half of severe COVID-19 patients in this research are male. Majority of the severe COVID-19 patients had chronic underlying conditions. Wheeze was the clinical feature of severe COVID-19 patients with influenza IgM-positive (26.4% vs 9.0%, P = 0.008). On contrary, fatigue or myalgia was the feature of the COVID-19 patients without IgM-positive (38.4% vs 58.2%, P = 0.019). In laboratory examination, increased levels of ferritin and prolonging APTT were showed in severe COVID-19 patients without influenza IgM-positive compared with patients in the other group with significant differences. Death rate in the group of severe COVID-19 patients with influenza IgM-positive is higher than it is in other group with significant differences (14.9% vs 4.1%, P = 0.040). In univariate regression analysis, several factors were associated with higher risk of death, which included LDH, troponin, NT-proBNP, D-dimer, PT, APTT, lymphocytes, platelet and eGFR. However, influenza virus IgM positive was associated with lower risk of death. Multivariate Regression analysis showed that troponin and lymphocyte were independently associated with higher risk of death.Conclusion The characteristics of patients hospitalized with severe COVID-19 with identification of influenza virus IgM-positive were described. It hints proof of seasonal influenza which may overlap with COVID-19 and may cause a crisis we could confront in the future.


Subject(s)
Emergencies , Death , Myalgia , COVID-19 , Fatigue
SELECTION OF CITATIONS
SEARCH DETAIL